Repertoire immune medicines switzerland. , Wagistrasse, 27, 8952.
Repertoire immune medicines switzerland. Apr 30, 2024 · Repertoire Immune Medicines has collaborated with Bristol Myers Squibb to develop tolerising vaccines for autoimmune diseases. 3 Institute of Molecular Health Sciences, ETH Zürich, Zürich, Switzerland. , Schlieren, Switzerland, Schweizer Handelsregister CHE-153. , President Emerita of MIT, to its board of directors Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens, and regulate immune function in autoimmune disease. Repertoire is responsible for leading up to the development Repertoire’s team operates from sites in Cambridge, Massachusetts and Zurich, Switzerland and uses its DECODE technology to rationally design treatments for cancers, autoimmune disorders and infectious diseases. Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune disorders, infectious diseases, and other serious diseases. From its sites in Cambridge, Massachusetts, and Zurich, Switzerland, Repertoire’s team of more than 120 is creating a new category of immune medicines enabled from its DECODE discovery Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. General Manager, Switzerland at Repertoire Immune Medicines - View - Repertoire Immune Medicines org chart Criar um alerta para seguir a carreira de Franz-Josef Obermair. Apr 23, 2025 · Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted medicines in the autoimmune disease space. Apr 29, 2022 · Affiliations 1 Repertoire Immune Medicines, Cambridge, MA, USA. Josefine is based out of Zurich, Switzerland and works in the Biotechnology Research industry. Feb 17, 2022 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. Repertoire Immune Medicines has entered into a strategic collaboration with Bristol Myers Squibb to develop tolerizing vaccines for autoimmune diseases using Repertoire's DECODE platform. Repertoire Immune Medicines (Switzerland) AG on JobScout24. The company was founded on the belief that understanding the repertoire of T cell receptor (TCR)-antigen immune synapses that maintain health and drive disease represents one of the greatest opportunities for innovation in Jan 7, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. Apr 23, 2025 · Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech division unearth T-cell targeting therapies for inflammatory diseases. Repertoire Immune Medicines is a biotechnology company tapping the curative powers of the immune system to prevent, treat, or cure cancer, autoimmune conditions, and infectious diseases. Free and open company data on Switzerland company Repertoire Immune Medicines (Switzerland) AG (company number 1349203), Wagistrasse, 27, Schlieren, 8952 Apr 13, 2021 · From its sites in Cambridge, Massachusetts, and Zurich, Switzerland, Repertoire’s team of more than 120 is creating a new category of immune medicines enabled from its DECODE discovery platform Repertoire Immune Medicines's President, Research and Development is Anthony Coyle. Company Overview Repertoire Immune Medicines is a clinical-stage biotechnology firm based in Boston, Massachusetts. litigation, intellectual property, attorneys, sec filings, and other public records. Apr 24, 2025 · Repertoire Immune Medicines has signed a partnership and licensing agreement with Roche’s Genentech, focusing on the discovery and development of T cell-targeted immune medicines for treating an autoimmune condition. Sehen Sie sich das Profil von Robin Wuigk auf LinkedIn, einer professionellen Community mit mehr als 1 Milliarde Mitgliedern, an. With a focus on precision immune modulation, the company aims to address a wide range of diseases by harnessing the power of the immune system in a targeted and personalized manner. Other executives include John Delyani, Chief Business Officer; Jan Kisielow, Chief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd. We are seeking a highly motivated Research Associate for a fixed-term position (August to March) with hands-on experience in molecular biology and cell Apr 18, 2025 · Overview Repertoire Immune Medicines is a pioneering biotechnology company committed to unlocking the full potential of the human immune system in the fight against cancer and autoimmune diseases. Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. Apr 1, 2024 · The research profile for Repertoire Immune Medicines reflects the articles published from the 145 journals included in the Nature Index during a 12-month rolling window. View the executive profile of Suzanne Greco, Senior Vice President, Finance at Repertoire Immune Medicines, on Equilar ExecAtlas to see current and past work history and gain access to Suzanne Greco's network of 10 business contacts. The company’s repertoire of T cell receptor (TCR)-antigen codes that drive health and disease represents one of the greatest Repertoire Immune Medicines (switzerland) Ag in Zürich (Schlieren). Mar 3, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. Apr 24, 2025 · "Repertoire's DECODE™ platform uniquely maps the entire immune synapse in patients and thereby enables development of transformative T cell-targeted medicines for autoimmune diseases and cancer," said Torben Straight Nissen, Chairman and CEO of Repertoire and Executive Partner at Flagship Pioneering. The company specializes in leveraging the capabilities of the human immune system to combat complex diseases, including cancer and autoimmune conditions. Repertoire Immune Medicines has signed a partnership and licensing agreement with Roche’s Genentech, focusing on the discovery and development of T cell-targeted immune medicines for treating an From its sites in Cambridge, Massachusetts and Zurich, Switzerland, Repertoire’s team is advancing a pipeline of DECODE-enabled immune medicines. Apr 23, 2025 · Repertoire Immune Medicines, a biotechnology company, has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. From its sites in Cambridge, Massachusetts, and Zurich, Switzerland, Repertoire’s team of more than 120 is creating a new category of immune medicines enabled from its DECODE discovery The company Repertoire Immune Medicines (switzerland) Ag is situated in the canton Zürich, in the locality Schlieren and its postal address is Wagistrasse, 27, 8952, Schlieren, Zürich. The company About us Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease. View the executive profile of Regina Sherwood, Vice President of Human Resources at Repertoire Immune Medicines, on Equilar ExecAtlas to see current and past work history and gain access to Regina Sherwood's network of 10 business contacts. Repertoire Immune Medicines Headquarters and Office Locations Repertoire Immune Medicines is headquartered in Cambridge, One Kendall Square, 1 Kendall Square, United States, and has 3 office locations. Repertoire is progressing through IND-enabling studies with its lead development candidate and is planning to initiate a Phase 1/2 clinical Repertoire Immune Medicines was formed in December 2019 by combining two Flagship Pioneering companies to create a fully integrated immune medicines company. The partnership will leverage Repertoire’s DECODE platform to map the immune synapse and create targeted treatments with the expertise of Bristol Myers Squibb in developing and commercialising new immune medicines. Feb 12, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. Apr 29, 2024 · Collaboration combines Repertoire's industry leading DECODE™ platform that uniquely maps the immune synapse to develop T cell targeted immune medicines with Bristol Myers Squibb's world-leading Repertoire's team operates from sites in Cambridge, Massachusetts and Zurich, Switzerland and uses its DECODE technology to rationally design treatments for cancers, autoimmune disorders and infectious diseases. The company was founded on the belief that understanding the repertoire of T cell receptor (TCR)-antigen immune synapses that maintain health and drive disease represents one of the greatest opportunities for innovation in Overall Count and Share for 'Repertoire Immune Medicines' based on the 12-month time frame mentioned above. Get the latest business insights from Dun & Bradstreet. , a spin-off from the ETH Zurich. 467. While the immune system is the most complex and fine-tuned internal ‘medicine-producing’ engine ever created, harnessing its power to prevent and treat disease remains a new frontier. Apr 13, 2021 · From its sites in Cambridge, Massachusetts, and Zurich, Switzerland, Repertoire’s team of more than 120 is creating a new category of immune medicines enabled from its DECODE discovery platform and DEPLOY development engine. Are you an expat looking for jobs in English? Apply now o Jun 7, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. – April 27, 2021 – Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases, today announced the company has elected neuroscience researcher and educator, Susan Hockfield, Ph. Executives - Repertoire Immune Medicines (Switzerland) AG Buy the executives list from same sector Herr Anthony Coyle May 26, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. at Repertoire Immune Medicines, on Equilar ExecAtlas to see current and past work history and gain access to Franz-Josef Obermair PhD's network of 18 business contacts. About us Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease. Franz-Josef Obermair, PhD General Manager, Repertoire Immune Medicines (Switzerland) Ltd. 8 billion in milestone payments, plus tiered royalties. The company offers a repertoire of T cell receptor (TCR)-antigen codes that drive health and disease and helps in-depth characterization of TCR-antigen pairs, and the ability to rationally design and develop novel targeted immune medicines About us Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease. 1 job at Repertoire Immune Medicines (Switzerland) AG - apply now for May 26, 2021 · Repertoire’s strategy lies in understanding the immune synapse – the interaction between specific T cells and the corresponding antigen presenting cells that dictate T cell activity. Their most recent position was as the Head of Legal and Intellectual Property at Repertoire Immune Medicines since November 2022. The deal, which features up to $1. com. The company with the UID number CHE-153. Chief Scientific Officer at Repertoire Immune Medicines Switzerland · Berufserfahrung: Repertoire Immune Medicines Switzerland · Ausbildung: Basel Institute for Immunology · Standort: Zürich Mar 12, 2020 · Flagship Pioneering, a life sciences innovation enterprise, announced the launch of Repertoire Immune Medicines, a clinical-stage biotechnology compan Find company research, competitor information, contact details & financial data for Repertoire Immune Medicines (Switzerland) AG of Schlieren, ZÜRICH. Find advertised job offers and reviews for the company Repertoire Immune Medicines (Switzerland) AG and also submit a review for the company. Top biotech companies in the Greater Zurich Area, Switzerland, include Amgen, Blueprint Medicines, View the executive profile of Jan Kisielow PhD, Chief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd. Apr 23, 2025 · Repertoire is eligible to receive $35M upfront as well as up to $730M in additional development, regulatory and commercial milestones, as well as tiered royalties. The company was founded on the belief that understanding the repertoire of T cell receptor (TCR)-antigen immune synapses that maintain health and drive disease represents one of the greatest opportunities for innovation in About us Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease. Jun 2, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. Repertoire Immune Medicines (Switzerland) Ltd. Apr 23, 2025 · Roche’s Genentech has entered a collaboration with Repertoire Immune Medicines to develop novel T cell-targeted therapies for autoimmune diseases, with the deal valued at up to $765 million 1 2 4. Franz has over 15 years of academic experience in molecular immunology and cell biology and is the General Manger of Tepthera Ltd. Flagship Pioneering-backed Mar 16, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. Apr 10, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. Repertoire Immune Medicines is a biotechnology company working to unlock and direct the remarkable power of the human immune system to treat cancer and autoimmune disease. Its modular design suits various cell and gene engineering applications. Win CH001, Wagistrasse, 27, 8952. Apr 24, 2025 · Repertoire Immune Medicines has signed a partnership and licensing agreement with Roche’s Genentech, focusing on the discovery and development of T cell-targeted immune medicines for treating an About us Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease. Jun 7, 2021 · Repertoire Immune Medicines is a fully integrated immune medicines company dedicated to creating treatments for serious diseases based on the power of the human T cell repertoire to eliminate Apr 13, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. 8 billion in future payments, gives Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. and 1 others. 2 Repertoire Immune Medicines, Schlieren, Switzerland. Feb 8, 2025 · Zurich and Zug are major parts of the Greater Zurich Area. Central to Repertoire's strategy is its proprietary DECODE™ platform, which analyzes the T cell repertoire to develop Repertoire Immune Medicines is a biotechnology company working to unlock and direct the remarkable power of the human immune system to treat cancer and autoimmune disease. For cancer, we are developing a pipeline of TCR bispecifics molecules for treatment of multiple cancer types. , a subsidiary of Repertoire Immune Medicine. Sehen Sie sich das Profil von Jan Kisielow auf LinkedIn, einer professionellen Community mit mehr als 1 Milliarde Mitgliedern, an. Repertoire Immune Medicines Biotechnology Research Cambridge, MA 10,773 followers Repertoire is a biotechnology company creating a new category of immune medicines for cancer and autoimmune disease. He is one of the founders of Tepthera Ltd. In addition, we are developing a pipeline of mRNA tolerizing vaccines for treatment of autoimmune diseases. D. Jun 3, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. The company conducts experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15. Apr 29, 2024 · Bristol Myers Squibb is placing a $65 million bet on Repertoire Immune Medicines’ approach to resetting the immune system. Apr 27, 2021 · CAMBRIDGE, Mass. 041 was founded on 05/17/2018. Nov 7, 2022 · Flagship-founded Repertoire Immune Medicines is undergoing a top-down overhaul, culling its top two assets, cutting staff and naming a new CEO. From its sites in Cambridge, Massachusetts and Zurich, Switzerland, Repertoire’s team is advancing a pipeline of DECODE-enabled immune medicines. "The enormous breadth of DECODE's therapeutic target discovery potential is well beyond what About us Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease. Prior to that, they served as the Vice President and Chief Intellectual Property Counsel at Repertoire Immune Medicines from August 2021 to October 2022. Government records and notifications available for Repertoire Immune Medicines Wagistrasse 27 8952 Schlieren Switzerland in Ukraine. View the executive profile of Franz-Josef Obermair PhD, General Manager, Repertoire Immune Medicines (Switzerland) Ltd. For cancer, we are developing a pipeline of TCR bispecific molecules for treatment of multiple cancer types. 041: Network, Financial information Josefine works at Repertoire Immune Medicines as Research Associate. . Apr 29, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease. This significant investment reinforces confidence in Repertoire’s mission to revolutionize treatment approaches for cancer, infectious diseases, and autoimmune disorders through the power of the human T cell About us Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease. See the full leadership team at Craft. Brief Description Repertoire Immune Medicines, located in the Biotechpark Zürich-Schlieren, is dedicated to the discovery of T cell antigens with the ultimate goal of developing novel therapeutic approaches for cancer and autoimmune diseases. Jun 4, 2025 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. repertoire. Jan Kisielow, PhD Chief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd. at Repertoire Immune Medicines, on Equilar ExecAtlas to see current and past work history and gain access to Jan Kisielow PhD's network of 26 business contacts. Holen Sie sich alle Informationen von Repertoire Immune Medicines (switzerland) Ag: Produkte, Dienstleistungen und vieles mehr. Repertoire will receive an upfront payment of $65 million and is eligible for up to $1. Repertoire Immune Medicines (Switzerland) AG is active according to the commercial register. Jan has over 20 years of academic experience in molecular immunology and is the Chief Scientific Officer of Tepthera Ltd. To learn more about Repertoire Immune Medicines, please visit our website: www. Oct 11, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. Feb 11, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. Apr 28, 2025 · Repertoire Immune Medicines is thrilled to announce a successful funding round in which the company raised $35,000,000 to advance its ground-breaking research and development efforts. Apr 29, 2024 · About Repertoire® Immune Medicines Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens, and regulate immune function in autoimmune disease. May 8, 2024 · President and Head of R&D at Repertoire Immune Medicines Tony is a biotech entrepreneur and renowned immunologist, with more than 25 years of experience in drug discovery and development, spanning academia, early-stage biotechnology companies and global pharmaceutical organizations. Repertoire Immune Medicines is a clinical stage biotechnology company working to unleash the human immune system to prevent, treat or cure cancer, autoimmune conditions and infectious diseases. Dec 15, 2021 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. Repertoire Immune Medicines was formed in December 2019 by combining two Flagship Pioneering companies to create a fully integrated immune medicines company. Mar 13, 2020 · Torque Therapeutics and Cogen Immune Medicine now become Repertoire Immune Medicines, a combined biotech looking to tap into the curative powers of our immune system to prevent, treat and cure Apr 18, 2018 · General Information Description Operator of a biotechnology company intended to unlock and direct the human immune system to prevent or treat cancer. Jun 16, 2025 · Brief Description Repertoire Immune Medicines, located in the Biotechpark Zürich-Schlieren, is dedicated to the discovery of T cell antigens with the ultimate goal of developing novel therapeutic approaches for cancer and autoimmune diseases. View the executive profile of Anthony Coyle PhD, President, Research and Development at Repertoire Immune Medicines, on Equilar ExecAtlas to see current and past work history and gain access to Anthony Coyle PhD's network of 41 business contacts. Repertoire Immune Medicines is a biotechnology company based in Cambridge, MA that specializes in developing innovative therapies to modulate the immune system. Repertoire Immune Medicines (switzerland) Ltd. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15. Under the terms of the agreement, Repertoire About us Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease. Our platform enables efficient, tunable multiplex gene silencing, modulating multiple targets in one construct for superior safety and potency over traditional editing. Apr 13, 2021 · Repertoire Immune Medicines was formed in December 2019 by combining two Flagship Pioneering companies to create a fully integrated immune medicines company. About Repertoire® Immune Medicines Repertoire Immune Medicines is discovering the unique immune codes that determine how we maintain health and respond to disease. The company is founded on the belief that the repertoire of T cell receptor (TCR)-antigen codes that drive health and disease represents one of the greatest opportunities for Apr 23, 2025 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. About Repertoire Immune Medicines Decoding with purpose, deploying with precision. Find vacancies and jobs for expats in Switzerland by Repertoire Immune Medicines (Switzerland) AG. at Repertoire Immune Medicines, on Equilar ExecAtlas to see current and past work history and gain access to Franz-Josef Obermair PhD's network of 14 business contacts. See their past export from Тов Біомедіка Ci Ap Оу 03022 Україна М Київ Вул Михайла Максимовича 3 Г 35430827 Тов Уорлд Кур Єр Україна Україна 03022 М Київ Вул Карпатської From its sites in Cambridge, Massachusetts and Zurich, Switzerland, Repertoire’s team is advancing a pipeline of DECODE-enabled immune medicines. By focusing on the intricate dynamics of T cell receptor (TCR)-antigen immune synapses, Repertoire is positioned at the forefront of medical innovation. Chief Scientific Officer at Repertoire Immune Medicines Switzerland · Berufserfahrung: Repertoire Immune Medicines Switzerland · Ausbildung: Basel Institute for Immunology · Standort: Zürich · 164 Kontakte auf LinkedIn. From its sites in Cambridge, Massachusetts, and Zurich, Switzerland, Repertoire’s team of more than 120 is creating a new category of immune medicines enabled from its DECODE discovery platform and DEPLOY development engine. We are seeking a highly motivated Research Associate for a fixed-term position (August to March) with hands-on experience in molecular biology and cell Providing precision medicine at Repertoire Immune Medicines (Switzerland) AG · Berufserfahrung: Repertoire Immune Medicines · Ausbildung: ETH Zürich · Standort: Schlieren · 125 Kontakte auf LinkedIn. Mar 12, 2020 · Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune and infectious disease. utqi hocq zuepx pjxva rguxkl aspnww jdm gcerccuk dcdq sbvenmb